GlassScriptPhysician profile
Vinita Singh
NPI 1679507248
$2,752.00
in general payments reported to CMS, 2019-2025
40 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $224 · 2021: $120 · 2023: $92.41 · 2024: $309 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $275.00 | 2025 | Rytelo |
| Janssen Biotech, INC. | $237.92 | 2019-2025 | Rybrevant, Carvykti, Akeega |
| Pfizer INC. | $232.87 | 2019-2025 | |
| Incyte Corporation | $201.07 | 2019-2025 | Jakafi, Jakafi |
| Gilead Sciences, INC. | $170.83 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $125.95 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $122.16 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Celgene Corporation | $112.86 | 2024-2025 | Reblozyl, Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $106.84 | 2019-2025 | |
| Genentech USA, INC. | $104.17 | 2019-2025 | Itovebi, Tecentriq |
| Eisai INC. | $96.93 | 2019-2023 | |
| Glaxosmithkline, LLC. | $81.02 | 2023-2025 | Ojjaara |
| Rigel Pharmaceuticals, INC. | $71.47 | 2019-2021 | |
| Array Biopharma INC | $71.46 | 2023-2024 | Braftovi, Mektovi, Tukysa |
| Karyopharm Therapeutics INC. | $67.09 | 2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $56.87 | 2025 | Mi Cancer Seek |
| Dendreon Pharmaceuticals LLC | $47.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.86 | 2019 | |
| Exelixis INC. | $37.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $36.54 | 2019 | |
| Taiho Oncology, INC. | $34.74 | 2019 | |
| Novocure INC. | $33.74 | 2019 | |
| Abbvie INC. | $33.71 | 2025 | |
| Amgen INC. | $30.59 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.22 | 2024 | Fruzaqla |
| Janssen Scientific Affairs, LLC | $29.29 | 2019 | |
| Tesaro, INC. | $26.62 | 2019 | |
| Verastem, INC. | $24.84 | 2019 | |
| Sobi, INC | $23.01 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.36 | 2024 | Libtayo |
| Teva Pharmaceuticals USA, INC. | $19.74 | 2020 | |
| Deciphera Pharmaceuticals INC. | $17.66 | 2023 | Qinlock |
| Seagen INC. | $17.49 | 2019 | |
| Beigene USA, INC. | $16.87 | 2020 | |
| Adc Therapeutics America, INC. | $16.67 | 2025 | |
| Sumitomo Pharma America, INC. | $16.66 | 2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $16.12 | 2023 | Fotivda |
| Daiichi Sankyo INC. | $14.26 | 2024 | Enhertu |
| Foundation Medicine, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinita Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.